Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 180 pages

Showing 51 - 100


solid tumors

2018 ASCO: IMPACT Trial Matches Treatment to Genetic Changes in the Tumor to Improve Survival Across Multiple Cancer Types

Researchers conducted a retrospective analysis of consecutive, prospectively molecularly profiled patients with advanced cancer who participated in a large, personalized medicine trial. They found that using molecular tests of tumors to select targeted therapy resulted in slower cancer growth and...

solid tumors

FDA Accepts Larotrectinib New Drug Application and Grants Priority Review

The U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) and granted Priority Review for larotrectinib in the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. ...

solid tumors

FDA Grants Fast Track Designation to Debio 1347 for Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration

Debiopharm International SA (Debiopharm) recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Debio 1347, an inhibitor of fibroblast growth factor receptors 1, 2, and 3 (FGFR1–3), for the treatment of patients with unresectable or...

solid tumors

FDA Approves Dabrafenib/Trametinib Combination for BRAF-Positive Anaplastic Thyroid Cancer

Today, the U.S. Food and Drug Administration approved dabrafenib (Tafinlar) and trametinib (Mekinist), administered together, for the treatment of unresectable, metastatic, BRAF V600E mutation–positive anaplastic thyroid cancer. Anaplastic thyroid cancer accounts for about 1% to 2% of all...

solid tumors

FDA Grants Orphan Drug Designation to BN-Brachyury for the Treatment of Chordoma

On May 2, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to the cancer vaccine BN-Brachyury for the treatment of chordoma. Chordoma is a rare type of cancer that develops along the spine, with presentation occurring at one of three main sites: sacrum, mobile spine, or...

solid tumors
hematologic malignancies

Update Regarding Tazemetostat Clinical Program

On April 23, Epizyme, Inc, announced that U.S.-based enrollment of new patients into tazemetostat clinical trials is temporarily on hold. Following a safety report of a pediatric patient who developed a secondary lymphoma, the U.S. Food and Drug Administration (FDA) issued a partial clinical hold...

solid tumors
immunotherapy

AACR 2018: Dual Inhibition of IDO1 and PD-L1 Safe in Patients With Advanced Solid Tumors

Treatment combining the IDO1 inhibitor epacadostat and the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) was found to be safe in patients with advanced solid tumors, with safety data similar to treatment with durvalumab alone, according to data presented from the ongoing...

solid tumors
lung cancer

AACR 2018: Selective Inhibitor Shows Early Promise in Patients With RET-Altered Cancers

BLU-667, a next-generation inhibitor that selectively targets the oncogenic receptor tyrosine kinase RET, was well tolerated and had broad clinical benefit in patients with advanced cancer that had progressed on previous therapies, including multikinase inhibitor therapy. Proof-of-concept data from ...

solid tumors

Comprehensive Genomic-Profiling Assay FoundationOne CDx Is Commercially Available

On March 30, Foundation Medicine announced that FoundationOne CDx, the first U.S. Food and Drug Administration (FDA)-approved comprehensive genomic-profiling assay for all solid tumors incorporating multiple companion diagnostics, is now available in the United States. FoundationOne CDx is a...

solid tumors

SSO 2018: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Frozen section evaluation of sentinel lymph nodes after neoadjuvant chemotherapy has a higher false-negative rate than in the primary surgical setting, particularly for small tumor deposits. However, it is unknown whether similar false positive rates occur after chemotherapy. Researchers led by...

solid tumors

EAU 2018: Study Finds a Quarter of Penile Cancer Patients Do Not Receive Recommended Treatment

A major international survey has found that around a quarter of patients with penile cancer are not receiving the recommended treatment, and that these patients had half the survival rate of those who were treated according to guidelines. The study, presented at the European Association of Urology...

solid tumors

Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease

Testicular cancer is the most common cancer in young men. The majority of patients are cured of their disease, but a newly published study shows many remain at risk for later complications from chemotherapy or other treatments. The study, published by Zaid et al in JNCCN –Journal of the...

solid tumors

Poorer Socioeconomic Status May Predict Lower Survival in Patients With Anal Cancer

Patients with lower income have a significantly reduced chance of surviving anal cancer, according to a new study led by investigators at NYU Langone Health’s Perlmutter Cancer Center published by Lin et al in the journal Cancer. The study shows that both overall and...

solid tumors
hematologic malignancies

AACR 2018: Prior Chemotherapies May Impair Pediatric Patients’ Ability to Develop Effective CAR T Cells

Pediatric patients with solid tumors may have poor quality T cells compared to patients with leukemia, and certain chemotherapies were detrimental to the T cells and their potential to become chimeric antigen receptor (CAR) T cells, according to data presented during a media preview for the...

solid tumors

TAT 2018: EXPRESS Study Explores the Genomic Landscape of Patients Achieving an 'Exceptional' Response to Targeted Therapy

The level of genomic alterations in genes associated with the oncogenesis of specific solid tumor types is being investigated in patients that have demonstrated an exceptional response to currently approved targeted therapies, researchers announced at the International Congress on Targeted...

solid tumors
lymphoma
immunotherapy

FDA Approves sBLA Updating Nivolumab Dosing Schedule Across Indications

On March 6, Bristol-Myers Squibb announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the nivolumab (Opdivo) dosing schedule to include 480 mg infused every 4 weeks for a majority of approved indications. This approval will ...

solid tumors

Study Shows Need for Early Supportive Care in Patients Diagnosed With Uveal Melanoma

In a study published by Williamson et al in JAMA Ophthalmology, University of California, Los Angeles, (UCLA) researchers found that nearly all patients diagnosed with uveal melanoma had a number of unmet psychological and health information needs, particularly during the first 3 months after their ...

solid tumors

Jeffrey M. Holzbeierlein, MD, on Penile, Urethral, and Testicular Cancers: Abstract Roundup

Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy in clinical stage I testicular cancer, the impact of Medicaid expansion on diagnosis and management of patients with...

solid tumors
immunotherapy

Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results

Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.

solid tumors
immunotherapy

Jeffrey M. Lemons, MD, on Solid Tumors: Safety Data on SBRT and Immunotherapy

Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body radiotherapy in patients with advanced solid tumors (Abstract 20).

solid tumors

Updated SCOUT Trial Data Demonstrate Response to Larotrectinib in TRK Fusion Cancers

At the Special Conference on Pediatric Cancer Research, convened in Atlanta by the American Association for Cancer Research, investigators announced updated clinical data from the larotrectinib (LOXO-101) pediatric phase I SCOUT trial. Bayer and Loxo Oncology are jointly developing larotrectinib,...

solid tumors

FDA Announces Approval, CMS Proposes Coverage of First Breakthrough-Designated Test to Detect Extensive Number of Cancer Biomarkers

On November 30, the U.S. Food and Drug Administration (FDA) approved the FoundationOne CDx (F1CDx), the first breakthrough-designated, next-generation sequencing–based in vitro diagnostic test that can detect genetic mutations in 324 genes and 2 genomic signatures in any solid tumor type. The ...

solid tumors

FDA Authorizes MSK-IMPACT Tumor Profiling Assay

Today, the U.S. Food and Drug Administration (FDA) authorized Memorial Sloan Kettering Cancer Center’s MSK-IMPACT tumor profiling assay, an in vitro diagnostic test that can identify more biomarkers that may be found in various cancers than any test previously reviewed by the...

solid tumors

AACR-NCI-EORTC: NCI-MATCH Reaches Central Patient-Screening Goal

The National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) clinical trial has achieved the goal of screening nearly 6,000 patients in just under 2 years, according to data presented by Chen et al at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer...

solid tumors

AACR-NCI-EORTC: Noninvasive Computational Imaging Approach May Help Predict Response to Immunotherapy

A computational imaging-based signature of immune-cell infiltration in and around a tumor could predict patients’ responses to treatment with anti–programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapies, according to data from a study presented by Sun et...

solid tumors

AACR-NCI-EORTC: Tazemetostat as Treatment for Certain Pediatric Relapsed or Refractory Solid Tumors

Children with relapsed or refractory malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas with a particular genetic defect tolerated treatment with the investigational drug tazemetostat well, and some had objective and durable responses, according to data from a phase ...

solid tumors

Potential Treatment of Chordoma With PI3K Inhibitors

Patients with chordoma—a rare bone cancer of the skull and spine—could be helped by existing treatments, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal National Orthopaedic Hospital NHS Trust. In the largest...

solid tumors

ASTRO 2017: Radiation-Immunotherapy Combination May Benefit Some Patients With Late-Stage Cancer

A new study involving patients with stage IV cancer has found that treatment with radiation therapy and immunotherapy can slow tumor growth by stimulating the body’s immune system to attack the cancer. In the phase II trial, patients with end-stage cancer that had metastasized to the lungs or ...

solid tumors

Detection of Early-Stage Cancers With Circulating Tumor DNA

In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...

solid tumors
hematologic malignancies

Clonal Hematopoiesis in Patients With Nonhematologic Cancers

In a study of nearly 9,000 people treated for solid tumors, researchers found that radiation treatment and tobacco use were linked to higher rates of blood-based DNA mutations that could lead to a higher risk for blood cancers such as leukemia. The study, published by Coombs et al in...

solid tumors
issues in oncology

Cancer at Baseline Screening in Patients With Li-Fraumeni Syndrome

In a new study from the National Cancer Institute (NCI), researchers found a higher-than-expected prevalence of cancer at baseline screening in individuals with Li-Fraumeni syndrome, a rare inherited disorder that leads to a higher risk of developing certain cancers. The research demonstrates...

solid tumors

NCI-COG Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers

Today, investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore...

solid tumors

COX-2 Inhibitors May Reverse IDO1-Mediated Immunosuppression in Some Cancers

In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain subsets of T cells, making them more likely to respond to...

breast cancer
solid tumors

CDK4/6 Inhibitors Have a Manageable Toxicity Profile, Are Generally Well Tolerated in Patients With Breast Cancer

A class of oral drugs for treating breast cancer known as cyclin-dependent kinase (CDK) 4/6 inhibitors are generally well-tolerated, with a manageable toxicity profile for most patients. This is the conclusion of a comprehensive review of toxicities and drug interactions related to this class of...

solid tumors
issues in oncology

ASTRO Updates Insurance Coverage Recommendations for Proton Therapy

The American Society for Radiation Oncology (ASTRO) has issued an update to its recommendations for medical insurance coverage regarding the use of proton beam therapy to treat cancer. The updated Proton Beam Therapy Model Policy provides guidance to payers on clinical indications that are...

solid tumors

FDA Grants 510(k) Clearance to Halcyon IMRT Treatment System

Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Halcyon system, a new device for cancer treatment. Halcyon simplifies and enhances image-guided volumetric-intensity modulated radiotherapy (IMRT). “We are proud that Halcyon has now...

solid tumors

FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy

On July 3, the U.S. Food and Drug Administration (FDA) cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss during chemotherapy. This is the first cooling cap cleared by the agency for use in cancer patients with solid tumors. “We are pleased to expand the...

solid tumors

SNMMI 2017: Combining PRRT With a PARP Inhibitor May Slow Neuroendocrine Tumor Growth

Patients with neuroendocrine tumors may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more sensitive to radiation therapy, said researchers at the 2017 Annual Meeting of the Society of Nuclear...

solid tumors
pancreatic cancer

SNMMI 2017: Immuno-PET Shows Promise for Detecting and Treating Pancreatic Tumors, Other Solid Tumors

A first-in-human study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Abstract 385) demonstrated the feasibility and safety of imaging with the novel human monoclonal antibody HuMab-5B1, to enable highly specific targeting for the cancer...

solid tumors
lymphoma
multiple myeloma

ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators

ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. “We are very pleased with the...

solid tumors

David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results

David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and pediatric cancers. (Abstract LBA2501)

solid tumors

ASCO 2017: Larotrectinib Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers

Scientists may have developed the first targeted, oral, tumor-type agnostic therapy—an agent that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment...

solid tumors

ASCO 2017: New High-Intensity Genomic Sequencing Approach Detects Circulating Tumor DNA at a High Rate

In a study of 124 patients with advanced breast, lung, and prostate cancers, a new high-intensity genomic sequencing approach detected circulating tumor DNA at a high rate. In 89% of patients, at least one genetic change detected in the tumor was also detected in the blood. Overall, 627 (73%)...

solid tumors
survivorship

ASCO 2017: Low Testosterone Level After Testicular Cancer Is Common, Linked to Chronic Health Problems

In a large study, 38% of 491 testicular cancer survivors had low testosterone levels. Compared with survivors with normal testosterone levels, survivors with low testosterone levels were more likely to have a range of chronic health problems, including high blood pressure, diabetes, erectile...

colorectal cancer
solid tumors

FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site-Agnostic Indication

On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...

solid tumors
hematologic malignancies

AACR 2017: IDH-Mutant Cancers May Be More Amenable to Treatment With PARP Inhibitors Than IDH Inhibitors, According to Preclinical Findings

Tumors with mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to BRCA-mutant tumors and were more likely to respond better to PARP inhibitors than to IDH inhibitors, according to preclinical data presented by Sulkowski et al at the 2017 American...

solid tumors

AACR 2017: Cancer Type and Mutation Identity Influenced Response to Neratinib in a Basket Clinical Trial

In the phase II SUMMIT clinical trial, the likelihood that a patient’s cancer responded to the investigational pan-HER–targeted therapeutic neratinib was influenced by both the cancer type and the identity of the gene mutation present in the cancer, according to results presented by...

solid tumors

First-in-Human Clinical Trial of ONC201 in Patients With Refractory Solid Tumors

A first-in-human clinical trial examining the investigational small-molecule drug ONC201 in patients with advanced solid tumors showed the oral agent to be well tolerated at the recommended phase II dose, according to Rutgers Cancer Institute of New Jersey investigators whose research also showed...

solid tumors

Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.

solid tumors

Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherapy.

Advertisement

Advertisement



Advertisement